Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,553,434
  • Shares Outstanding, K 143,922
  • Annual Sales, $ 330,530 K
  • Annual Income, $ -145,220 K
  • EBIT $ -490 M
  • EBITDA $ -517 M
  • 60-Month Beta 1.40
  • Price/Sales 10.55
  • Price/Cash Flow N/A
  • Price/Book 2.64

Options Overview Details

View History
  • Implied Volatility 90.22% ( +11.22%)
  • Historical Volatility 59.78%
  • IV Percentile 95%
  • IV Rank 85.73%
  • IV High 96.66% on 05/01/24
  • IV Low 51.56% on 07/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 2,327
  • Open Int (30-Day) 2,478

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.80
  • Number of Estimates 13
  • High Estimate -0.46
  • Low Estimate -0.97
  • Prior Year -0.86
  • Growth Rate Est. (year over year) +6.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.53 +4.93%
on 11/19/24
33.33 -25.92%
on 11/11/24
-1.60 (-6.09%)
since 10/22/24
3-Month
23.53 +4.93%
on 11/19/24
33.33 -25.92%
on 11/11/24
+0.80 (+3.35%)
since 08/22/24
52-Week
14.56 +69.57%
on 04/25/24
33.33 -25.92%
on 11/11/24
+6.59 (+36.41%)
since 11/22/23

Most Recent Stories

More News
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

DNLI : 24.69 (+1.94%)
Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Bio-Techne has underperformed the healthcare sector over the past year, yet analysts remain strongly bullish about the stock’s prospects.

TECH : 71.28 (+0.32%)
XLV : 144.16 (+0.09%)
DNLI : 24.69 (+1.94%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 24.69 (+1.94%)
FHTX : 7.84 (+1.55%)
MRNA : 41.11 (+7.48%)
OMGA : 0.7860 (+1.29%)
SANA : 2.61 (+11.06%)
MCRB : 0.7686 (+5.03%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 24.69 (+1.94%)
FHTX : 7.84 (+1.55%)
MRNA : 41.11 (+7.48%)
OMGA : 0.7860 (+1.29%)
SANA : 2.61 (+11.06%)
MCRB : 0.7686 (+5.03%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 24.69 (+1.94%)
FHTX : 7.84 (+1.55%)
MRNA : 41.11 (+7.48%)
OMGA : 0.7860 (+1.29%)
SANA : 2.61 (+11.06%)
MCRB : 0.7686 (+5.03%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 24.69 (+1.94%)
FHTX : 7.84 (+1.55%)
MRNA : 41.11 (+7.48%)
OMGA : 0.7860 (+1.29%)
SANA : 2.61 (+11.06%)
MCRB : 0.7686 (+5.03%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 24.69 (+1.94%)
FHTX : 7.84 (+1.55%)
MRNA : 41.11 (+7.48%)
OMGA : 0.7860 (+1.29%)
SANA : 2.61 (+11.06%)
MCRB : 0.7686 (+5.03%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 24.69 (+1.94%)
FHTX : 7.84 (+1.55%)
MRNA : 41.11 (+7.48%)
OMGA : 0.7860 (+1.29%)
SANA : 2.61 (+11.06%)
MCRB : 0.7686 (+5.03%)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 24.69 (+1.94%)
RARE : 47.24 (+2.65%)
SRPT : 114.23 (+3.38%)
PFE : 25.65 (+2.07%)
EXEL : 35.61 (+2.24%)
MRNA : 41.11 (+7.48%)
UTHR : 372.89 (+1.51%)
BIIB : 157.90 (-0.07%)
SNY : 48.28 (+0.63%)
LLY : 748.01 (-0.25%)
Why Shares of Denali Therapeutics Are Up Monday

Analysts maintained their buy ratings on the clinical-stage biotech company.

DNLI : 24.69 (+1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 25.72
2nd Resistance Point 25.22
1st Resistance Point 24.96
Last Price 24.69
1st Support Level 24.20
2nd Support Level 23.70
3rd Support Level 23.44

See More

52-Week High 33.33
Fibonacci 61.8% 26.16
Last Price 24.69
Fibonacci 50% 23.95
Fibonacci 38.2% 21.73
52-Week Low 14.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar